Brought to you by 
Shire licenses Giuliani's ulcerative colitis mesalazine
18 Jan 2007
Executive Summary
Shire Pharmaceuticals (CNS, oncology, and anti-infective therapeutics) licensed rights in North America, Europe outside of Italy, and Japan, to develop, manufacture, and sell Giuliani SPA's Phase II mesalazine MMX system for treating ulcerative colitis. Shire gets a one-year option to add rights in the Pacific Rim (which it subsequently exercised).
Deal Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire licenses Giuliani's ulcerative colitis mesalazine
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice